Anti-IL-23p19 treatment prevented the onset and expansion of AAA with the same efficiency as IL-12p40 antagonism, suggesting that the efficacy of anti-IL-12p40 treatment may reflect IL-23 inhibition. Here, IL23A is linked to triple-A syndrome.